Emerging Psychobiotics: Direct and Indirect Impacts on Mental Health

Kimia Ghaderi[1,*] - Samira Fayazfar[2] *Omidreza Noroozi[3]*
[1]Student of Food Hygiene, SR.C., Islamic Azad University, Tehran, IRAN
[2] Department of Food Hygiene, SR.C., Islamic Azad University, Tehran, IRAN
[3]Student of Food Hygiene, SR.C., Islamic Azad University, Tehran, IRAN

ABSTRACT

*Anxiety, stress, and depression constitute a significant global health burden, with projections suggesting a continued rise in prevalence and societal impact in the coming decade. While conventional pharmacological and psychological interventions offer relief, their limitations, including side effects and treatment resistance, underscore of novel therapeutic avenues. This comprehensive review aims to examine the direct and indirect mechanisms through which psychobiotics—live microorganisms, prebiotics, or synbiotics that confer mental health benefits—exert their influence on the brain-gut axis to ameliorate symptoms of anxiety, stress, and depression. We synthesize evidence from preclinical and clinical studies, highlighting the critical role of specific bacterial strains such as *Lactobacillus helveticus R0052*, *Bifidobacterium longum R0175*, *Lactobacillus casei Strain Shirota*, and *Limosilactobacillus fermentum L18* in modulating neurotransmitter production (GABA, serotonin, dopamine), reducing inflammation, and regulating the hypothalamic-pituitary-adrenal (HPA) axis. Furthermore, the review discusses the indirect effects of psychobiotics through enhancement of gut barrier integrity and modulation of the overall gut microbiota composition. While promising, the field faces challenges related to study heterogeneity and the need for personalized approaches. This review concludes that psychobiotics, with their multifaceted actions, hold substantial promise as future interventions, either as monotherapies or adjuncts, in the management of these pervasive neuropsychiatric conditions.*

Keywords: Psychobiotics, Gut-brain axis, Neurotransmitters

1. *INTRODUCTION*

The 21st century has witnessed a steadily increasing global burden of mental health disorders, particularly anxiety, stress-related conditions, and major depressive disorder. These conditions are projected to remain among the leading causes of disability worldwide, posing substantial challenges to public health systems and individual well-being throughout the decade of 2025 and beyond [1]. Although current therapeutic strategies—such as antidepressants, anxiolytics, and psychotherapy—are effective for many individuals, they are often limited by delayed onset of action, undesirable side effects, and a considerable proportion of patients who exhibit only partial or no response to treatment [2]. Consequently, there is an urgent need to explore innovative and complementary approaches to improve treatment outcomes and strengthen mental resilience.

Emerging research has revealed the intricate and bidirectional communication network between the gut microbiota and the central nervous system collectively referred to as the "Microbiota–Gut–Brain (MGB) axis" [3, 4]. This axis forms a compelling foundation for the development of novel interventions aimed at modulating the gut in order to influence brain function and mental health.

Within this paradigm, "psychobiotics" have garnered substantial attention. Defined as either live microorganisms that, when consumed in adequate amounts, confer mental health benefits to individuals with psychiatric disorders, or as substances (e.g., prebiotics, synbiotics, postbiotics) that promote the growth and activity of such beneficial microbes, psychobiotics represent a rapidly evolving field.

This review aims to comprehensively evaluate the direct and indirect effects of psychobiotics on anxiety, stress, and depression, drawing upon recent mechanistic insights and clinical evidence. By examining strain-specific actions and underlying biological mechanisms, we aim to evaluate the potential of psychobiotics as a promising and transformative therapeutic approach for managing these prevalent neuropsychiatric conditions.

1. The Microbiota-Gut-Brain (MGB) Axis: A Bidirectional Communication Highway

The Microbiota–Gut–Brain (MGB) axis represents a complex neuroendocrine and neuroimmune system that integrates signals from the gut microbiota with central nervous system functions, thereby influencing mood regulation, cognitive processing, and behavior [3, 4]. Communication along this axis occurs through multiple, intricately interconnected pathways, including neural and endocrine routes.

1.1.NeuralPathways:

The vagus nerve, a major component of the parasympathetic nervous system, serves as a direct and rapid communication channel between the gut and the brain. Microbial-derived metabolites and signaling molecules can activate afferent vagal fibers, thereby influencing specific brain regions implicated in emotional regulation and stress response [5].

1.2.Endocrine Pathways:

The MGB axis modulates the hypothalamic–pituitary–adrenal (HPA) axis, the central regulator of the stress response. Dysregulation of HPA axis activity and chronically elevated cortisol levels are frequently observed in individuals with anxiety and depression [6]. Certain gut microbial species and their metabolites can influence HPA axis reactivity, thereby altering the physiological stress response.

1.3.Immune Pathways:

The gut microbiota plays a crucial role in shaping the host's immune system. Dysbiosis (an imbalance in gut microbiota composition) can lead to increased intestinal permeability ("leaky gut"), allowing bacterial components to enter the systemic circulation. This can trigger a low-grade systemic inflammation, which is increasingly recognized as a contributing factor to the pathophysiology of depression and anxiety [7]. Psychobiotics can modulate immune responses and reduce pro-inflammatory cytokine levels.

1.4.Metabolic Pathways:

Gut microbes produce a vast array of metabolites, including short-chain fatty acids (SCFAs) like butyrate, propionate, and acetate, as well as various neurotransmitters or their precursors. These metabolites can cross the blood-brain barrier (BBB) or signal via enteroendocrine cells, directly impacting brain function [8]. Fermented foods, rich in beneficial microbes and their metabolites, are increasingly recognized for their potential to influence the gut and mental health through these diverse mechanistic pathways [9].

2. Direct Mechanisms of Action of Psychobiotics on Mental Health

Psychobiotics exert their effects through direct modulation of neurobiological processes implicated in anxiety, stress, and depression.

2.1. Neurotransmitter Modulation

A key mechanism involves the direct or indirect influence of psychobiotics on the synthesis and metabolism of central neurotransmitters.

*Gamma-Aminobutyric Acid (GABA): GABA is the primary inhibitory neurotransmitter in the central nervous system, playing a critical role in calming neural activity and reducing anxiety [10]. Several probiotic strains, particularly those from fermented foods, possess the enzymatic machinery to produce GABA. Research has focused on optimizing GABA production by various probiotic bacteria through methods like response surface methodology (RSM), demonstrating the potential for enhanced yields [11, 12]. For instance, *Limosilactobacillus fermentum L18* (formerly *Lactobacillus fermentum L18*), a potential* *probiotic strain of human origin, has been shown to produce significant amounts of GABA. Studies indicate that *L. fermentum L18* can exert beneficial effects by improving intestinal permeability and modulating the human gut microbiota, thereby indirectly contributing to GABA-mediated anxiolytic effects [13].*

Serotonin (5-Hydroxytryptamine, 5-HT): Serotonin is a crucial neurotransmitter regulating mood, sleep, appetite, and cognition. A substantial proportion of the body's serotonin is produced in the gut by enterochromaffin cells, influenced by gut microbial activity. Psychobiotics can manipulate serotonin signaling by modulating its precursors (e.g., tryptophan availability), influencing its synthesis, or affecting its receptors in the gut, which can have downstream effects on brain serotonin levels [14].

Dopamine: Dopamine is vital for reward, motivation, and executive functions. The MGB axis also plays a significant role in regulating dopaminergic signaling. Certain gut bacteria can produce dopamine precursors or influence dopaminergic pathways, highlighting another avenue through which psychobiotics might impact mood and cognitive function [15].

2.2. Reduction of Inflammation

Chronic low-grade inflammation is increasingly recognized as a crucial factor in the pathogenesis of depression and anxiety [7]. Psychobiotics can mitigate inflammation through several mechanisms:

Enhancing Gut Barrier Integrity: By strengthening tight junctions between intestinal epithelial cells, psychobiotics reduce "leaky gut," thereby preventing the translocation of bacterial toxins (e.g., lipopolysaccharide, LPS) into the bloodstream, which can trigger systemic inflammation [13].

Modulating Immune Cell Responses: Psychobiotics can interact directly with immune cells in the gut-associated lymphoid tissue (GALT), influencing the balance of pro-inflammatory and anti-inflammatory cytokines. This can lead to a reduction in systemic inflammation, which subsequently benefits brain health [9].

2.3. HPA Axis Regulation

Hyperactivity of the HPA axis is a hallmark of chronic stress, anxiety, and depression. Psychobiotics have been shown to modulate the HPA axis, leading to reduced stress responses and lower circulating cortisol levels. This can occur through direct neural signaling (via the vagus nerve) or indirectly by reducing inflammatory signals that activate the HPA axis [6, 9].

3. Indirect Impacts of Psychobiotics on Mental Health

Beyond direct neurochemical modulation, psychobiotics exert indirect influences that collectively contribute to improved mental well-being.

3.1. Modulation of Gut Microbiota Composition and Diversity

*A diverse and balanced gut microbiota is associated with better mental health outcomes. Psychobiotics can reshape the microbial community by promoting the growth of beneficial bacteria while inhibiting pathogenic ones. For instance, consumption of fermented milk containing *Lactobacillus casei Strain Shirota* has been shown to preserve the diversity of the gut microbiota in healthy medical students exposed to academic stress, simultaneously relieving abdominal dysfunction—a common stress-related symptom [16]. This microbial resilience can contribute to enhanced physiological and psychological stress coping.*

3.2. Enhancing Intestinal Barrier Function

*As previously mentioned, an intact intestinal barrier is critical for preventing systemic inflammation. Psychobiotics, such as *Limosilactobacillus fermentum L18*, have demonstrated beneficial effects on intestinal permeability, which indirectly contributes to reducing the inflammatory burden on the host and potentially mitigating neuroinflammation associated with mental health disorders [13].*

3.3. Production of Short-Chain Fatty Acids (SCFAs)

SCFAs, primarily acetate, propionate, and butyrate, are key microbial metabolites produced through the fermentation of dietary fibers. These molecules act as signaling molecules, influencing gut integrity, immune function, and brain health. Butyrate, in particular, serves as a primary energy source for colonocytes and has anti-inflammatory properties. SCFAs can also modulate gene expression in the brain, impacting neurotransmitter synthesis and neuronal plasticity, thereby playing an indirect role in mood regulation [8, 9].

5. Clinical Evidence and Strain-Specific Effects

Human clinical trials investigating the impact of psychobiotics on mood and cognition have yielded promising, albeit sometimes heterogeneous, results. These studies often highlight the importance of strain specificity, demonstrating that not all probiotics confer the same psychological benefits.

*Targeting Stress and Anxiety: A randomized controlled trial investigated the psychotropic-like properties of a specific probiotic formulation comprising *Lactobacillus helveticus R0052* and *Bifidobacterium* *longum R0175*. This combination demonstrated anxiolytic and antidepressant-like effects in both rat models and human subjects, leading to a reduction in psychological distress and stress-related gastrointestinal symptoms. The observed effects were attributed to the modulation of the HPA axis and reduced inflammatory markers [17].*

Alleviating Academic Stress: The consumption of fermented milk containing Lactobacillus casei Strain Shirota is beneficial in mitigating the effects of academic stress in healthy individuals. Beyond preserving gut microbiota diversity, this specific strain helped to alleviate stress-induced abdominal dysfunction, suggesting a protective role against physiological manifestations of stress [16].*

Impact on Mood and Cognition: General consumption of milk drinks containing probiotics has shown potential to positively impact mood and cognitive function, although the specific mechanisms and strain contributions require further elucidation [18]. Furthermore, multispecies probiotic formulations have been tested for their effects on cognitive reactivity to sad mood. Such studies reveal the complexity of probiotic interventions, suggesting that specific combinations might be necessary to address particular psychological outcomes [19].

These studies underscore that the efficacy of psychobiotics is highly dependent on the specific strain or combination of strains, the dosage, and the target population. While preliminary, the findings provide a strong rationale for further investigation into defined psychobiotic interventions.

6. Challenges and Future Directions

Despite the burgeoning interest and promising results, the field of psychobiotics faces several challenges that need to be addressed to realize its full therapeutic potential:

Heterogeneity of Studies: A major hurdle is the wide variability in study designs, probiotic strains used, dosages, durations of intervention, and outcome measures across different trials. This makes direct comparisons and meta-analyses difficult [20].

Strain Specificity vs. Broad-Spectrum Effects: While evidence points towards strain-specific effects, a deeper understanding of which specific strains are most effective for particular mental health conditions is crucial. Future research needs to precisely characterize the mechanisms of action for individual strains or defined consortia [21].

Dosing and Formulation: Optimal dosing regimens, delivery methods, and the stability of psychobiotics in different formulations remain important areas of research.

Personalized Medicine: Given the unique composition of each individual's gut microbiota, a personalized approach to psychobiotic intervention, potentially guided by pre-treatment microbiota profiling, may yield superior results.

Need for Larger, Well-Designed RCTs: There is a critical need for larger-scale, randomized, placebo-controlled clinical trials with robust methodologies, objective biomarkers, and long-term follow-up to conclusively establish efficacy and safety in diverse patient populations.

Regulatory Framework: Clearer regulatory guidelines for psychobiotics, distinct from traditional food supplements, are essential to ensure product quality and efficacy claims are evidence-based.

Conclusion

*The evidence presented in this review strongly supports the growing recognition of psychobiotics as a compelling and innovative approach to managing anxiety, stress, and depression. The direct and indirect modulation of the MGB axis through mechanisms involving neurotransmitter synthesis (e.g., GABA by *Limosilactobacillus fermentum L18*), inflammation reduction, and HPA axis regulation, coupled with documented clinical improvements in mood and stress parameters by specific strains like *Lactobacillus helveticus R0052*, *Bifidobacterium longum R0175*, and *Lactobacillus casei Strain Shirota*, underscore their therapeutic potential.*

As we look towards 2025 and beyond, psychobiotics offer a promising future intervention, potentially serving as valuable adjuncts to conventional therapies or even as primary interventions for specific patient subsets. However, a concerted effort towards rigorous, hypothesis-driven research, focusing on strain-specific effects, mechanistic elucidation, and personalized applications, is indispensable. By overcoming current challenges, psychobiotics have the capacity to transform mental healthcare, offering a holistic and gut-centric approach to alleviate the pervasive burden of anxiety, stress, and depression in the modern era.

REFERENCES

[1] *World Health Organization. (2017). Depression and other common mental disorders:global health estimates. World Health Organization. (General knowledge, widely cited for prevalence).*

[2] *Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR* D report. American Journal of Psychiatry. 2006;163(11):1905–17.*

[3] *Cryan JF, Dinan TG. Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nature reviews neuroscience. 2012;13(10):701–12.*

[4] *Dinan TG, Cryan JF. The microbiome-gut-brain axis in health and disease. Gastroenterology Clinics. 2017;46(1):77–89.*

[5] *Bravo JA, Forsythe P, Chew MV, Escaravage E, Savignac HM, Dinan TG, et al. Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proceedings of the National Academy of Sciences. 2011;108(38):16050–5.*

[6] *Foster JA, Neufeld K-AM. Gut–brain axis: how the microbiome influences anxiety and depression. Trends in neurosciences. 2013;36(5):305–12.*

[7] *MAES M, DROLET G. The neuro-inflammatory and neuroprogressive pathways in depression. Progress in neuro-psychopharmacology & biological psychiatry. 2011;35(3).*

[8] *Silva YP, Bernardi A, Frozza RL. The role of short-chain fatty acids from gut microbiota in gut-brain communication. Frontiers in endocrinology. 2020;11:508738.*

[9] *Aslam H, Green J, Jacka FN, Collier F, Berk M, Pasco J, et al. Fermented foods, the gut and mental health: a mechanistic overview with implications for depression and anxiety. Nutritional neuroscience. 2020;23(9):659–71.*

[10] *Lydiard RB. The role of GABA in anxiety disorders. Journal of Clinical Psychiatry. 2003;64:21–7.*

[11] *Devi PB, Rajapuram DR, Jayamanohar J, Verma M, Kavitake D, Avany BAM, et al. Gamma-aminobutyric acid (GABA) production by potential probiotic strains of indigenous fermented foods origin and RSM based production optimization. Lwt. 2023;176:114511.*

[12] *Sharafi S, Nateghi L. Optimization of gamma-aminobutyric acid production by probiotic bacteria through response surface methodology. Iranian Journal of Microbiology. 2020;12(6):584.*

[13] *Kaur S, Sharma P, Mayer MJ, Neuert S, Narbad A, Kaur S. Beneficial effects of GABA-producing potential probiotic Limosilactobacillus fermentum L18 of human origin on intestinal permeability and human gut microbiota. Microbial Cell Factories. 2023;22(1):256.*

[14] *Everett BA, Tran P, Prindle A. Toward manipulating serotonin signaling via the microbiota–gut–brain axis. Current Opinion in Biotechnology. 2022;78:102826.*

[15] *Bercik P, Denou E, Collins J, Jackson W, Lu J, Jury J, et al. The intestinal microbiota affect central levels of brain-derived neurotropic factor and behavior in mice. Gastroenterology. 2011;141(2):599–609. e3.*

[16] *Kato-Kataoka A, Nishida K, Takada M, Kawai M, Kikuchi-Hayakawa H, Suda K, et al. Fermented milk containing Lactobacillus casei strain Shirota preserves the diversity of the gut microbiota and relieves abdominal dysfunction in healthy medical students exposed to academic stress. Applied and environmental microbiology. 2016;82(12):3649–58.*

[17] *Messaoudi M, Lalonde R, Violle N, Javelot H, Desor D, Nejdi A, et al. Assessment of psychotropic-like properties of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in rats and human subjects. British journal of nutrition. 2011;105(5):755–64.*

[18] *Benton D, Williams C, Brown A. Impact of consuming a milk drink containing a probiotic on mood and cognition. European journal of clinical nutrition. 2007;61(3):355–61.*

[19] *Steenbergen L, Sellaro R, van Hemert S, Bosch JA, Colzato LS. A randomized controlled trial to test the effect of multispecies probiotics on cognitive reactivity to sad mood. Brain, behavior, and immunity. 2015;48:258–64.*

[20] *Wallace CJ, Milev R. The effects of probiotics on depressive symptoms in humans: a systematic review. Annals of general psychiatry. 2017;16(1):14.*

[21] *Taylor AM, Holscher HD. A review of dietary and microbial connections to depression, anxiety, and stress. Nutr Neurosci. 2020;23(3):237–50.*